Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 101.98% is in line with its 5-year average of 100.00%, around the middle of its 5-year range (-2580.68%–2763.57%).
9.72% above its 12-month average of 92.95%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
101.98%
GROSS MARGIN AVG TTM
92.95%
GROSS MARGIN AVG 3Y
100.00%
GROSS MARGIN AVG 5Y
100.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+9.72%
CURRENT VS 3Y AVG
+1.98%
CURRENT VS 5Y AVG
+1.98%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 736 covered companies
CURRENT VS SECTOR MEDIAN
+151.00%
vs the sector median at left
Kymera Therapeutics, Inc.
Market Cap
$8.68B
Gross Margin
101.98%
TTM Avg
92.95%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$8.77B
Gross Margin
100.00%
TTM Avg
-161.83%
3Y Avg
-33.28%
5Y Avg
-5.52%
Market Cap
$8.92B
Gross Margin
99.86%
TTM Avg
98.67%
3Y Avg
99.34%
5Y Avg
99.56%
Market Cap
$8.39B
Gross Margin
14.38%
TTM Avg
17.24%
3Y Avg
38.82%
5Y Avg
59.22%
Market Cap
$9.03B
Gross Margin
93.24%
TTM Avg
91.97%
3Y Avg
90.98%
5Y Avg
60.65%
Market Cap
$9.05B
Gross Margin
46.69%
TTM Avg
47.45%
3Y Avg
49.39%
5Y Avg
49.15%
Market Cap
$9.32B
Gross Margin
46.69%
TTM Avg
47.45%
3Y Avg
49.39%
5Y Avg
49.15%
Market Cap
$8.00B
Gross Margin
69.66%
TTM Avg
54.89%
3Y Avg
42.48%
5Y Avg
46.51%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | $8.68B | 101.98% | 92.95% | 100.00% | 100.00% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.77B | 100.00% | -161.83% | -33.28% | -5.52% |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.92B | 99.86% | 98.67% | 99.34% | 99.56% |
| Oscar Health, Inc. (OSCR)vs › | $8.39B | 14.38% | 17.24% | 38.82% | 59.22% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $9.03B | 93.24% | 91.97% | 90.98% | 60.65% |
| Bruker Corporation (BRKRP)vs › | $9.05B | 46.69% | 47.45% | 49.39% | 49.15% |
| Bruker Corporation (BRKR)vs › | $9.32B | 46.69% | 47.45% | 49.39% | 49.15% |
| Caris Life Sciences, Inc. (CAI)vs › | $8.00B | 69.66% | 54.89% | 42.48% | 46.51% |
| Insulet Corp. (PODD)vs › | $9.38B | 71.08% | 70.71% | 67.87% | 67.39% |
| Vaxcyte, Inc. (PCVX)vs › | $9.44B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
102.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 100.00% |
| 2025-12-31 | 2763.57% |
| 2025-09-30 | -2580.68% |
| 2025-06-30 | 81.84% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | 100.00% |
| 2023-06-30 | 100.00% |
| 2023-03-31 | 100.00% |
| 2022-12-31 | 100.00% |
| 2022-09-30 | 100.00% |
| 2022-06-30 | 100.00% |
| 2022-03-31 | 100.00% |
| 2021-12-31 | 100.00% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 100.00% |
| 2019-09-30 | 100.00% |
